Y.D. More Investments Ltd Buys 882 Shares of Kenvue Inc. (NYSE:KVUE)

Y.D. More Investments Ltd raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 15.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 6,513 shares of the company’s stock after purchasing an additional 882 shares during the period. Y.D. More Investments Ltd’s holdings in Kenvue were worth $139,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Leo Wealth LLC lifted its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares in the last quarter. Alerus Financial NA lifted its holdings in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC lifted its holdings in Kenvue by 1.9% during the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares in the last quarter. Wolff Wiese Magana LLC boosted its position in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares during the period. Finally, LS Investment Advisors LLC increased its stake in shares of Kenvue by 1.1% in the third quarter. LS Investment Advisors LLC now owns 51,745 shares of the company’s stock worth $1,197,000 after purchasing an additional 570 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $20.74 on Thursday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm’s fifty day moving average is $21.77 and its 200 day moving average is $21.96. The company has a market cap of $39.76 billion, a price-to-earnings ratio of 37.70, a PEG ratio of 2.05 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on KVUE shares. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. UBS Group dropped their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.